Actively Recruiting
Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer
Led by National Cancer Institute, Naples · Updated on 2025-03-25
3100
Participants Needed
1
Research Sites
103 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study involves the use of reagents or materials for diagnostic assessments that are not commercially available, specifically a metabolomic signature for screening endometrial carcinoma and/or other types of cancers, and follows a case-control design. This study aims to achieve several objectives that contribute to evaluating the diagnostic potential of a specific "metabolomic signature" to be used for screening endometrial carcinoma. Specifically, the study seeks to assess the signature's discriminative ability in differentiating between benign endometrial neoplasms and neoplasms of different histological origins.
CONDITIONS
Official Title
Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female sex
- Age between 50 and 80 years
- Willingness to participate in the study and signing of the informed consent
- Clinical condition of post-menopause
You will not qualify if you...
- Previous hysterectomy
- Hormone replacement therapy
- Immunosuppressive therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Istituto Nazionale Tumori | "Fondazione Pascale"
Naples, Italy, 80131
Actively Recruiting
Research Team
A
Antonella De Luca
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here